skip to primary navigationskip to content
 

Understanding the Biotechnology Industry: Lecture by Dr Simon Aspland, Acidophil Ltd

last modified Oct 31, 2016 01:40 PM

Join us for a lecture given by Dr Simon Aspland, General Manager of Acidophil Ltd and VP of Business Development. Acidophil semi-serially creates (e.g. AgriMetis), manages (e.g. Population Genetics), finances and commercializes new biotechnology products and businesses. Simon will describe aspects of Acidophil’s business model to illustrate various career options in biotechnology. He will also discuss internship opportunities at Acidophil in the form of three month projects for BBSRC DTP students (PIPS) and paid internships working no more than six hours a week.

About Acidophil:

Acidophil is a biotechnology innovation and commercialization company named after its founders Nobel Laureate Sydney Brenner MD Ph.D. and serial entrepreneur Philip Goelet Ph.D.  It has operations in the US (Baltimore, MD) and UK (Cambridge). Acidophil develops new products and businesses in health (e.g. Arginetix merged with Corridor Pharmaceuticals then sold to AstraZeneca) and agriculture (e.g. AgriMetis founded with Syngenta Ventures). 

About Simon:

Simon has worked in biotech for 15 years, co-founding and managing four biotechnology companies: Stell (technology acquired by Sangamo Biosciences), Arginetix, ZuvaChem (merged with BioSyntha) and AgriMetis.  Simon transitioned from the bench to company creation and management in 2006. Prior to his biotech career, he was a postdoctoral researcher at the University of California, San Diego following graduate and postdoctoral work at the University of Cambridge.

 

Date: Tuesday 22 November

Time: 14:00-15:30 (talk about one hour, followed by time for questions)

Venue: Large Lecture Theatre, Plant Sciences